Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
Not yet recruiting
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Xiyanping injection+ antibiotic
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 1140
- Registration Number
- NCT06754865
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: GP681 tabletDrug: GP681 Powder for Oral Suspension
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06678542
- Locations
- 🇨🇳
Women and Children's hospital of Ningbo University, Ningbo, China
Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: GP681 10mg/20mg/40mg
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06643156
- Locations
- 🇨🇳
Ningbo Women and Children's hospital, Ningbo, Zhejiang, China
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Phase 3
Recruiting
- Conditions
- Influenza
- Interventions
- Drug: GP681 SimulantDrug: GP681 40mg
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 748
- Registration Number
- NCT06574503
- Locations
- 🇨🇳
Shulan (Hang Zhou) Hospital, Hanzhou, China
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Phase 3
Recruiting
- Conditions
- Influenza, Human
- Interventions
- Drug: GP681 SimulantDrug: GP681 40mg
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 328
- Registration Number
- NCT06573008
- Locations
- 🇨🇳
The people's Hospital of Chizhou, Chizhou, China
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05814926
- Locations
- 🇨🇳
Beijing You'an Hospital, Beijing Medical University, Beijing, Beijing, China
A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05789342
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Drug: GP681 40mgDrug: Placebo
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 591
- Registration Number
- NCT05474755
- Locations
- 🇨🇳
The First People's Hospital of Wenling, Wenling, Zhejiang, China
A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C] GP681
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05103241
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04926506
© Copyright 2025. All Rights Reserved by MedPath